About the Post-Conference Report
- Our DDR analyst team have screened the data from ASH 2022 and have identified 27 abstracts (4 clinical and 23 preclinical) associated with trial or drug records on Beacon DDR.
- This post-conference report provides an analysis of the abstracts, assessed by asset, target and disease indication, followed by top-level summaries of the abstracts with links to their corresponding drug or trial page on the Beacon platform.
About Beacon Targeted Therapies
We are a clinical trial and pipeline database solution, designed in partnership with pharmaceutical professionals. We track targeted therapies to provide accurate, in-depth and real-time information in the rapidly evolving landscape of drug development.
Learn more about how our clinical trials and drug database solutions can be tailored to your research requirements